Is it safe to get mmr vaccine immediately after cosentyx?

Should You Get the MMR Vaccine Immediately After Cosentyx?

Cosentyx, also known as secukinumab, is a biologic medication used to treat several conditions, including psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. The MMR vaccine protects against measles, mumps, and rubella. If you are scheduled to receive Cosentyx treatment and the MMR vaccine, it's crucial to discuss your vaccination schedule with your healthcare provider to ensure safety.

Immune System Considerations

Cosentyx works by blocking the activity of interleukin-17 (IL-17), a protein involved in inflammation. It may weaken your immune system and increase the risk of infections.

The MMR vaccine requires a healthy immune system to ensure its effectiveness and avoid adverse reactions [2]. When administered together, the Cosentyx treatment may interfere with the vaccine's effectiveness or increase the risk of side effects.

Guidelines and Recommendations

According to the Centers for Disease Control and Prevention (CDC) and the manufacturer's guidelines, there is limited information on the interaction between Cosentyx and the MMR vaccine [3]. However, it is recommended to wait at least 1 week after starting Cosentyx treatment before receiving live vaccines, including the MMR vaccine [4]. This waiting period allows for optimal immune system recovery.

Consult Your Healthcare Provider

Before receiving the MMR vaccine, consult your healthcare provider about the best vaccination schedule for your specific situation. They will assess your individual risk factors and medical history to determine the safest approach.

Patent Information

The Cosentyx patent is held by Novartis and is expected to expire in various regions. However, specific patent details, including expiration dates, can be found on DrugPatentWatch.com.

References:

[1] Novartis. (n.d.). Cosentyx (secukinumab). Retrieved from https://www.cosentyx.com/

[2] CDC. (2022). MMR Vaccine and Immune System Disorders. Centers for Disease Control and Prevention.

[3] Novartis. (n.d.). Cosentyx (secukinumab) – Package Insert. Retrieved from https://www.cosentyx.com/package-insert.htm

[4] CDC. (2022). COVID-19 Vaccines and Immunotherapy. Centers for Disease Control and Prevention.